Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study.

Abstract

Multiple sclerosis (MS) has a significant impact on health-related quality of life (HRQoL) with symptoms adversely affecting many aspects of everyday living. BG-12 (dimethyl fumarate) demonstrated significant efficacy in the phase III studies DEFINE and CONFIRM in patients with relapsing-remitting MS. In CONFIRM, HRQoL was worse in patients with greater disability at baseline, and who relapsed during the study, and improved with BG-12 treatment. Mean Short Form-36 Physical Component Summary scores for BG-12 increased over 2 years and scores for placebo decreased. Coupled with clinical and neuroradiological benefits, these HRQoL results further support BG-12 as an effective oral treatment for relapsing MS.

• Authors: Mariko Kita, Robert J Fox, J Theodore Phillips, Michael Hutchinson, Eva Havrdova, Sujata P Sarda, Sonalee Agarwal, Jessica Kong, Annie Zhang, Vissia Viglietta, Sarah I Sheikh, Emily Seidman, Katherine T Dawson
• Journal: Multiple sclerosis (Houndmills, Basingstoke, England) (Mult Scler) Vol. 20 Issue 2 Pg. 253-7 (Feb 2014) ISSN: 1477-0970 [Electronic] England
• PMID: 24150778 (Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Fumarates
• Immunosuppressive Agents
• Dimethyl Fumarate

Topics

• Adult
• Dimethyl Fumarate
• Double-Blind Method
• Female
• Fumarates (therapeutic use)
• Humans
• Immunosuppressive Agents (therapeutic use)
• Male
• Middle Aged
• Multiple Sclerosis, Relapsing-Remitting (drug therapy)
• Quality of Life
• Surveys and Questionnaires
• Treatment Outcome